The Involvement of the Gut Hormone GIP in the Pathophysiology of Post Prandial Hypotension — GA-21  

PostPrandial Hypotension Clinical Trial

Official title: The Involvement of the Gut Hormone GIP in the Pathophysiology of Post Prandial Hypotension

Status Recruiting

Clinical Trial Summary

The present study investigates the involvement of the gut hormone glucose-dependent insulinotropic polypeptide (GIP) in the pathophysiology of postprandial hypotension (PPH)

Clinical Trial Description

The study is an exploratory, randomised, placebo-controlled, double-blind crossover study comprising two experimental days with an infusion of the GIP receptor antagonist, GIP(3-30)NH2 (NH2 is the aminogroup), and placebo (saline) during a 180-minute mixed meal test (MMT). Eighteen participants, men and women, with MMT confirmed PPH will be included in the study. ;

Related Conditions & MeSH terms

• Hypotension
• PostPrandial Hypotension

• NCT number: NCT06208904
• Study type: Interventional
• Source: University Hospital, Gentofte, Copenhagen
• Contact: Lise Wilki-Kurtzhals, MD
• Phone: +4526204303
• Email: lise.wilki-kurtzhals@regionh.dk
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2024
• Completion date: March 31, 2025